A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

2

Participants

Timeline

Start Date

October 21, 2015

Primary Completion Date

April 30, 2019

Study Completion Date

January 24, 2020

Conditions
Relapsed Solid TumorsRefractory Solid Tumors
Interventions
DRUG

Eribulin

Intravenous eribulin administered on days 1 and 8 of a 21-day cycle.

DRUG

Irinotecan

Irinotecan will be administered orally at a fixed dose of 90 mg/m2/day on days 1 -5 of a 21-day cycle.

OTHER

Cefixime

Cefixime will be given to all patients to reduce irinotecan-associated diarrhea. It will be administered Day -1 through Day 8 of each cycle.

Trial Locations (3)

40536

University of Kentucky, Lexington

80045

Children's Hospital Colorado, Aurora

Unknown

University of Texas, Southwestern Medical Center, Dallas

All Listed Sponsors
collaborator

University of Kentucky

OTHER

lead

University of Colorado, Denver

OTHER

NCT02596503 - A Study of Eribulin in Combination With Oral Irinotecan for Adolescent and Young Adult Patients With Relapsed or Refractory Solid Tumors | Biotech Hunter | Biotech Hunter